Showing 2691-2700 of 2894 results for "".
- Read Their Lips: Avoid Unnatural Lip Enhancement Results With This Datahttps://modernaesthetics.com/news/read-their-lips-avoid-unnatural-lip-enhancement-results-with-this-data/2472247/Many a Real Housewife from Bravo’s hit reality TV franchise have been chastised for trout pout – or an overfilled, unnatural looking pucker. And now a new study, published by JAMA Facial
- Restylane® Refyne and Restylane® Defyne Show Lasting Natural Benefit in Phase 4 Studieshttps://modernaesthetics.com/news/restylane-refyne-and-restylane-defyne-show-lasting-natural-benefit-in-phase-4-studies/2472251/Two Phase 4 clinical studies of Restylane® Refyne and Restylane® Defyne show that the natural-looking results last. Specifically, the Natural Expression study found that naturalness in facial expressions was at least main
- Breaking Business News: Apax Partners to Acquire Syneronhttps://modernaesthetics.com/news/breaking-business-news-apax-partner-to-acquire-syneron/2472253/An affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash in a transaction valued at approximately $397 million. The per share acquisition price represe
- BTL Aesthetics Unveils New Ultra Femme 360° Technology for Vaginal Rejuvenationhttps://modernaesthetics.com/news/btl-aesthetics-unveils-new-ultra-femme-360-technology-for-vaginal-rejuvenation/2472265/BTL Industries is introducing its new 360° technology to leading cosmetic dermatologists and physicians during the annual American Academy of Dermatology (AAD) Conference taking place in Orlando, FL, March 3rd – 7th, with th
- In a Week of Surprising Acquisitions, Will Syneron Be Next?https://modernaesthetics.com/news/in-a-week-of-surprising-acquisitions-will-syneron-be-next/2472276/Hot off the heels of Allergan’s acquisition of Zeltiq and Hologic Inc,’s surprising purchase of Cynosure Inc., media reports are now swirling that British private equity fund Apax Partners is looking to buy Syneron Medical for $350-$400 million. According to Israeli finan
- Allergan Agrees to Acquire ZELTIQ for $2.47 Billionhttps://modernaesthetics.com/news/allergan-agrees-to-acquire-zeltiq-for-247-billion/2472280/Allergan plc and ZELTIQ® Aesthetics, Inc. have entered into a definitive agreement under which Allergan has agreed to acquire ZELTIQ for $56.50 per share, or $2.475 billion, subject to customary
- Happy 10th Birthday Radiesse!https://modernaesthetics.com/news/happy-10th-birthday-radiesse/2472291/Merz Aesthetics’ flagship brand, Radiesse, turned 10 this year, and was feted in style at a throw-back Thursday media event in New York City. The party took beauty bloggers and journos back to 2007 when the first iPhone was releas
- Update: Revance Starts Phase III Studies on RT002 for Frown Lineshttps://modernaesthetics.com/news/revance-starts-phase-iii-studies-on-rt002-for-frown-lines/2472297/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials
- Revealed: What A Girl Wants in a Plastic Surgeonhttps://modernaesthetics.com/news/revealed-what-a-girl-wants-in-a-plastic-surgeon/2472307/Nearly half of all female plastic surgery patients have no preference when it comes to the gender of their cosmetic surgeon, a new study show. Specifically, the report, published in Aesthetic Surgery Journal</
- Merz On The Move: Reflections On Fiscal Year 2015/16https://modernaesthetics.com/news/merz-on-the-move-reflections-on-fiscal-year-201516/2472311/Merz Pharma’s core business has grown by 8.9 percent from EUR 809.8 million to EUR 881.9 million in fiscal 2015/16, the company reports. The company’s total revenue of EUR 1,092.9 million has declined by 5.5 percent compared to previous year